Effect of angiotensin receptor blockade on prevention and reversion of tamoxifen-resistant phenotype in MCF-7 cells
- 334 Downloads
Tamoxifen (TAM) is a standard adjuvant endocrine therapy in postmenopausal breast cancer patients, but innate or acquired TAM resistance has remained to be a therapeutic challenge for clinicians. The aim of this study was to explore the possible participation of renin-angiotensin system (RAS) in the acquisition of TAM resistance and try to prevent and regress the resistance using an angiotensin II receptor type-1 (AGTR1) blocker, losartan. Establishment of TAM-resistant (TAM-R) cells was accomplished by continuous exposure of MCF-7 cells to 1 μmol/L TAM. MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay was performed to determine cell growth. Moreover, messenger RNA (mRNA) expression levels of AGTR1 and angiotensin II receptor type-2 (AGTR2) were measured by quantitative real-time polymerase chain reaction. A significant increase of AGTR1 and AGTR2 transcripts was observed in TAM-R cells compared to MCF-7 cells. Interestingly, losartan-TAM combination effectively resensitized TAM-R cells to tamoxifen treatment by inducing cell death. Therefore, our findings suggest an important role of RAS in acquired TAM resistance and targeting of RAS by losartan may overcome TAM resistance phenomenon and provide a novel avenue for treatment of resistant breast cancers.
KeywordsBreast cancer Tamoxifen resistance Renin-angiotensin system Losartan MCF-7
This study was financially supported by grants from Shiraz University of Medical Sciences (no. 91-01-36-4902), Iran National Science Foundation (no. 90003070), and Institute for Cancer Research (ICR). The funding sources only financially supported this study and were not involved in the study design, data analysis, interpretation of data, writing, editing, and submission of the manuscript. This work contains parts of the doctoral thesis of Ebrahim Sahebi. The authors would like to thank Dr. Shirin Ardeshir-Rouhani-Fard for proof reading the manuscript.
Conflicts of interest
- 2.Iqbal J, Ginsburg OM, Wijeratne TD, Howell A, Evans G, Sestak I, et al. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev. 2012;38(4):318–28. doi: 10.1016/j.ctrv.2011.06.009.CrossRefPubMedGoogle Scholar
- 18.Choi CH, Park Y, Choi J-J, Song T, Song SY, Lee Y-Y, et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol. 2012;126(1):124–31. doi: 10.1016/j.ygyno.2012.04.020.CrossRefPubMedGoogle Scholar
- 19.Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am J Hypertens. 1999;12(12):1181–7. doi: 10.1016/S0895-7061(99)00142-9.CrossRefPubMedGoogle Scholar
- 20.Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Clin Ther. 2000;22(10):1186–203. doi: 10.1016/S0149-2918(00)83062-3.CrossRefPubMedGoogle Scholar
- 25.Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 2003;144(3):1032–44. doi: 10.1210/en.2002-220620.CrossRefPubMedGoogle Scholar
- 39.Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res. 2005;11(7):2686–94. doi: 10.1158/1078-0432.CCR-04-1946.CrossRefPubMedGoogle Scholar
- 41.Arrieta O, Guevara P, Escobar E, García-Navarrete R, Pineda B, Sotelo J. Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer. 2005;92(7):1247–52. doi: 10.1038/sj.bjc.6602483.CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Greco S, Muscella A, Elia M, Salvatore P, Storelli C, Mazzotta A, et al. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol. 2003;196(2):370–7. doi: 10.1002/jcp.10313.CrossRefPubMedGoogle Scholar
- 54.De Paepe B, Verstraeten VL, De Potter CR, Bullock GR. Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem Cell Biol. 2002;117(1):13–9. doi: 10.1007/s00418-001-0356-0.CrossRefPubMedGoogle Scholar